Colorectal cancer (CRC) is a significant global health burden, with stage III disease representing a setting where there is strong evidence to support the role of adjuvant chemotherapy in improving ...
What is the best upfront chemotherapy option for patients with colorectal cancer (CRC) and unresectable liver metastases? A new report demonstrated why patients benefit most from starting on a ...
In a phase III trial, a chemotherapy regimen of fluorouracil, oxaliplatin, and docetaxel (TFOX) improved survival outcomes over standard FOLFOX for patients with advanced HER2-negative gastric cancer.
BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in patients with HER2-negative gastric ...
Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of ...
A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastric cancer: Efficacy and safety analysis (BOLD-100-001). This is an ASCO Meeting Abstract from the ...
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback